Please login to the form below
tasimelteon
This page shows the latest tasimelteon news and features for those working in and with pharma, biotech and healthcare.
BMS' Opdivo backed as melanoma therapy in EU
Vanda Pharmaceuticals got the go-ahead for Hetlioz (tasimelteon) for the treatment of non-24-hour sleep wake disorder in totally blind adults - which was approved in the US last year -
Latest news
-
FDA approves sleep disorder drug for blind people
Vanda Pharmaceuticals is now allowed to market its drug Hetlioz (tasimelteon) to treat a condition called non-24-hour sleep-wake disorder, which causes problems in the sleep cycle of blind
-
FDA panel backs sleep pattern drug for blind
A Food Drug and Administration (FDA) advisory committee voted unanimously to recommend approval of Vanda Pharmaceuticals' Hetlioz (tasimelteon) for non-24-hour disorder (N24) in the totally blind. ... Tasimelteon acts on melatonin MT1/MT2 receptors and
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Salary TBC
-
Digital Account Director
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Project Manager/ Account Manager
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
-
Senior Medical Writer
-
Up to £50, 000 with Benefits
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Senior Medical Writer
-
Great salary and benefits
Subscribe to our email news alerts
- Lighthouse Medical Commuications US appoints Lisa Druce as its new Managing Partner
- GW Pharma's cannabis-based medicine to be tested in dementia
- International Childhood Cancer Day 2019
- AZ says dropping MedImmune will help ‘streamline’ its R&D
- Merck puts prostate cancer firmly in Keytruda’s sights
- Biosimilar Herceptin helps Roche gain new Perjeta recommendation
PMHub
Swordfish Advertising
At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...
Latest intelligence
- International Childhood Cancer Day 2019
- The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
- Immuno-oncology in 2019: the rapid evolution continues
- Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
- Mixing up Focus Groups
- A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...
Quick links
Infographics
